- $1.52bn
- $1.20bn
- $411.33m
Brief: Innoviva Reports Second Quarter 2021 Financial Results
Britain's GSK exits U.S. drugmaker Innoviva in $392 million deal (updated)
Brief: Innoviva Announces Strategic Repurchase Of GSK’S Equity Stake
Britain's GSK exits Innoviva stake in $392 million deal
Brief: GSK Announces Sale Of Stake In Innoviva Inc
Brief: Innoviva Reports Q1 EPS $0.84
Brief: Innoviva Reports Qtrly Diluted Net Income Per Share Attributable To Innoviva Stockholders $0.48
Brief: Armata Pharmaceuticals Announces $20 Million Investment To Support Advancement Of The Company's Bacteriophage Development Programs
Brief: Innoviva Inc Entered Into A Strategic Partnership With Sarissa Capital Management LP
Brief: Innoviva Reports Qtrly Earnings Per Share $0.26
Innoviva: Up as FDA expands inhaler approval for use in asthma patients
Brief: Innoviva Posts Quarterly Diluted Net Income Per Share Attributable To Innoviva Stockholders $0.69
Brief: Innoviva Names Pavel Raifeld As Chief Executive Officer
Brief: Innoviva Reports First Quarter 2020 Financial Results
Brief: Innoviva Says Co's 2020 Annual Meeting Of Stockholders Will Be Held In Virtual Meeting Format Only
Brief: GSK Says Filing Accepted By EMA For Trelegy Ellipta Use In Adult Patients With Asthma
Brief: Innoviva Reports Q4 Diluted Net Income Per Share $0.42
Armata Pharma: Soars to 1-yr high on $25 mln stocks and warrants deal
Brief: Armata And Innoviva Will Invest $25 Mln For Armata's Bacteriophage Development Programs